Clinical trials: Not Condition-specific
ALK-Positive Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type
Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas
This phase II trial studies how well nivolumab with or without varlilumab works in treating patients with aggressive B-cell lymphomas that have come back (recurrent) or do not respond to treatment (refractory).
- Conditions
- ALK-Positive Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type
- Trial name
- NCT03038672
- Testing
- Nivolumab, Varlilumab
- Where
- 33 sites in United States
- Volunteers
- 54 people
- Sponsor
- National Cancer Institute (NCI)
Autism, Asperger's Syndrome
Cognitive Behavioral Therapy for Anxiety Disorders in Adolescents With Autism
Due to the considerable prevalence of anxiety in youth with autism spectrum disorders, this study seeks to establish the efficacy of a modified cognitive behavioral therapy protocol in 50 adolescents versus other available…
- Conditions
- Autism, Asperger's Syndrome, Pervasive Developmental Disorder Not Otherwise Specified, Generalized Anxiety Disorder
- Trial name
- NCT01563003
- Testing
- Cognitive Behavioral Therapy, Treatment as usual
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- University of South Florida
Major Depression, Dysthymia
Dichotic Listening as a Predictor of Medication Response in Depression
Depressed patients will have hearing tests and then be treated with up to three treatments (i.e., Fluoxetine, Imipramine) until remitted, to see whether test results predict specific outcomes.
- Conditions
- Major Depression, Dysthymia, Depressive Disorder Not Otherwise Specified
- Trial name
- NCT00296725
- Testing
- Fluoxetine, Imipramine
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- New York State Psychiatric Institute
Major Depressive Disorder, Dysthymia
Safety and Efficacy Study of Citalopram and Lithium for the Treatment of Depressive Mood Disorder Symptoms
The investigators hypothesize that patients receiving citalopram in combination with lithium will have a greater reduction in depressive symptoms than patients receiving citalopram in combination with placebo.
- Conditions
- Major Depressive Disorder, Dysthymia, Depression Not Otherwise Specified, Borderline Personality Disorder
- Trial name
- NCT01189812
- Testing
- Lithium Carbonate, Citalopram
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Columbia Northwest Pharmaceuticals
B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma
This phase I/II trial studies the safety of acalabrutinib and axicabtagene ciloleucel in treating patients with B-cell lymphoma. Acalabrutinib may stop the growth of tumor cells by blocking key pathways needed for cell growth.
- Conditions
- B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma
- Trial name
- NCT04257578
- Testing
- Acalabrutinib, Axicabtagene Ciloleucel
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Washington
CNS Embryonal Tumor, Not Otherwise Specified, Malignant Glioma
Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors
This phase I trial studies the side effects and best dose of ribociclib and everolimus and to see how well they work in treating patients with malignant brain tumors that have come back or do not respond to treatment.
- Conditions
- CNS Embryonal Tumor, Not Otherwise Specified, Malignant Glioma, Recurrent Atypical Teratoid/Rhabdoid Tumor, Recurrent Childhood Ependymoma
- Trial name
- NCT03387020
- Testing
- Everolimus, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 12 sites in United States
- Volunteers
- 22 people
- Sponsor
- Pediatric Brain Tumor Consortium
Schizophrenia, Schizoaffective Disorder
Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study
The purpose of this study is to get a better understanding of the side effect burden and identify predictors of psychotic, mood and aggressive disorders in children and adolescents.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorder, Not Otherwise Specified
- Trial name
- SATIETY (NCT01269710)
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of North Carolina, Chapel Hill
Follicular Lymphoma, Marginal Zone Lymphoma
Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma
Oral clofarabine is related to two intravenous chemotherapy drugs used for this disease and works in two different ways. It affects the development of new cancer cells by blocking two enzymes that cancer cells need to reproduce.
- Conditions
- Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Small Lymphocytic Lymphoma
- Trial name
- NCT00644189
- Testing
- Clofarabine
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Massachusetts General Hospital
Anaplastic Large Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype
Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas
This phase I/II trial studies the side effects and best dose of pralatrexate when given together with pembrolizumab and how well they work in treating patients with peripheral T-cell lymphomas that has come back after a period of…
- Conditions
- Anaplastic Large Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma
- Trial name
- NCT03598998
- Testing
- Pembrolizumab, Pralatrexate
- Where
- 3 sites in United States
- Volunteers
- 13 people
- Sponsor
- City of Hope Medical Center
Pediatric Brain Tumor, Diffuse Intrinsic Pontine Glioma
A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG
This research study involves an investigational product: Ad-RTS-hIL-12 given with veledimex for production of human IL-12. IL-12 is a protein that can improve the body's natural response to disease by enhancing the ability of the…
- Trial name
- NCT03330197
- Testing
- Ad-RTS-hIL-12, Oral Veledimex - Arm 1 (Pediatric Brain Tumor), Oral Veledimex - Arm 2 (DIPG)
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- Alaunos Therapeutics
Autism Spectrum Disorder (ASD), Autism
Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
The objective of this study is to evaluate the long-term safety and tolerability of memantine in the treatment of pediatric patients with autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified…
- Conditions
- Autism Spectrum Disorder (ASD), Autism, Autistic Disorder, Asperger's Disorder
- Trial name
- NCT01592773
- Testing
- Memantine Hydrochloride (HCl)
- Where
- 106 sites in United States, Belgium and 14 more
- Volunteers
- 747 people
- Sponsor
- Forest Laboratories
HIV
Randomized Placebo-Controlled Trial of Atorvastatin in HIV-Positive Patients Not on Antiretroviral Therapy
This study will examine the effects of atorvastatin, a statin (drug that lowers cholesterol) on the human immunodeficiency virus (HIV).
- Trial name
- STATIN (NCT00367458)
- Testing
- Atorvastatin
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)